Introduction

Penile cancer (PC) is a rare and potentially disfiguring disease. There have been great strides made to improve cancer control, as well as to decrease treatment-associated morbidities. We present our outcomes using penile sparing surgery (PSS) for the treatment of PC in the largest cohort known to date.

Methods

1439 patients were retrospectively identified to have undergone PSS for PC from July 2000 to June 2015 at five international institutions of excellence. PSS consisted of laser ablation, wide local excision, circumcision, and partial/total glansectomy. Patient demographics and clinical characteristics were summarized using descriptive statistics. Univariate analyses were performed using the chi-square test for categorical variables. Kaplan Meier survival curves were applied to determine overall recurrence free survival (RFS) as well RFS stratified by pathologic stage and surgical intervention.

Results

Median patient age of our cohort was 63 years old. Median patient follow up was 40 months. 23.9% of all patients recurred after PSS. 5 year RFS by pT stage was Ta/Tis: 58.0%, T1: 55.5%, and T2: 49.8%. RFS for all patients undergoing PSS was 55.6%( 1 year: 77.3%, 2 year: 67.3%, 5 year: 55.6%). Treatment modality (p=0.056) and pT stage (p=0.99) did not significantly correlate with RFS at 5 years. Patients with higher pT tumors underwent more aggressive interventions (p <0.001).

Conclusions

PSS is indicated for appropriately selected patients with PC. Treatment modality and pT stage were not significant predictors of RFS. Close follow-up remains a critical component of all treatment considerations.

Funding

None